Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of entinostat when given
together with aldesleukin and to see how well this works in treating patients with kidney
cancer that has spread to other places in the body. Entinostat may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Aldesleukin may stimulate the
white blood cells to kill kidney cancer cells. Giving entinostat together with aldesleukin
may be a better treatment for metastatic kidney cancer.